Results of midodrin treatment of vasovagal syncope


如何引用文章

全文:

详细

Aim. To elicit efficacy ofmidodrin in patients with vasovagal syncope.
Material and methods. 50 patients with recurrent vasovagal syncope documented by head-up tilt tests
or bicycle exercise stress tests participated in the study. These tests controlled the effects ofmidodrin if
syncopes occurred again in repetition of the tests. In the other patients the effect of the drug was assessed clinically. All the patients received midodrin in daily dose up to 15 mg.
Results. Mirodrin effectively prevented syncope in 13 (72%) patients as shown by the tilt test, in 10
(59%) patients as shown by the exercise stress tests and in 14 (93%) patients as controlled clinically.
Total efficacy ofmidodrin was 74% (37 of 50 patients).
Conclusion. Midodrin demonstrated high efficacy in prevention of vasovagal syncope. Side effects were
not serious therefore the drug is well tolerated.

参考

  1. Wieling W., Ganzeboom K. S., Krediet С. Т. et al. Initial diagnostic strategy in the case of transient losses of consciousness: the importance of the medical history. Ned. Tijdschr. Geneesk. 2003; 147: 849-854.
  2. Ganzeboom K. S., Colman N, Reitsma J. B. et al. Prevalence and triggers of syncope in medical students. Am. J. Cardiol. 2003; 91: 1006-1008.
  3. Martin G. I., Adams S. L., Martin H. G. et al. Prospective evaluations of syncope. Ann. Emerg. Med. 1984; 13: 499.
  4. Kapoor W. N. Evaluation and outcome of patients with syncope. Medicine (Baltimore) 1990; 69: 160.
  5. Kapoor W. N. Syncope and hypotension. In: Braunwald E. (ed.) Heart disease. A textbook of cardiovascular medicine. 5- th ed. 1998. 863-876.
  6. Savage D. D., Corwin L., McGee D. L. et al. Epidemiologic features of isolated syncope: the Framingham study. Stroke 1985; 16: 626-629.
  7. Linzer M., Pontinen N, Gold D. T. et al. Impairment of physical and psychosocial function in recurrent syncope. J. Clin. Epidemiol. 1991; 44: 1037-1043.
  8. Brignole M., Alboni P., Benditt D. et al. Guidelines on management (diagnosis and treatment) of syncope. Eur. Heart J. 2001; 22: 1256-1306.
  9. Ward С R, Gray I. C, Gilroy J. J., Kenny P. A. Midodrine: a role in the treatment of neurocardiogenic syncope. Heart 1998; 79: 45-49.
  10. Kaufmann H., Saadia D., Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized crossover study. Ann. Neurol. 2002; 52: 342-345.
  11. Sheldon R., Rose S., Flanagan P. et al. Effects of beta blockers on the time to first syncope recurrence in patients after a posi tive isoproterenol tilt-table test. Am. J. Cardiol. 1996; 78: 536-539.
  12. Slotwiner D. J., Stein К. М., Lippman N. et al. Response of neurocardiac syncope to beta-blocker therapy: interaction be tween age and parasympathetic tone. Pace 1997; 20: 810-814.
  13. Mahanonda N., Bhuripanyo K, Kangkagate С et al. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am. Heart J. 1995; 130: 1250-1253.
  14. Brignole M., Menozzi C, Gianfranchi L. et al. A controlled trial of acute and long-term medical therapy in tilt-induced neurally mediated syncope. Am. J. Cardiol. 1992; 70: 339-342.
  15. Di Gerolamo E., Di Iorio C, Sabatini P. et al. Effects of differеnt treatments vs no treatment on neurocardiogenic syncope. Cardiologia 1998; 43: 833-837.
  16. Flevari P., Livanis E., Theodorakis G. et al. Neurocardiogenic syncope: prospective, randomized, cross-over evaluation of the effects of propranolol, nadolol and placebo on syncope recurrence and patients well-being (Abstr.) Pace 2000; 23: 666.
  17. Madrid A., Ortega I., Rebollo G. J. et al. Lack efficacy of atenolol for the prevention of neurally-mediated syncope in highly symptomatic population: a prospective double-blind, randomized and placebo-controlled study. J. Am. Coll. Cardiol. 2001; 37: 554-557.
  18. Jhamb D. K., Singh В., Sharda B. et al. Comparative study the efficacy of metoprolol and verapamil in patients with syncope and positive head-up tilt test response. Am. Heart J. 1996: 132: 608-611.
  19. Grubb B. P., Temesy-Armos P., Moore J. et al. The use of head-upright tilt table testing in the evaluation and management of syncope in children and adolescents. Pace 1992; 15: 742-748.
  20. Lee T. M., Su S. E, Chen M. F. et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am. J. Cardiol. 1996; 78: 480-482.
  21. Morillo С A., Leitch J. W., Yee R., Klein G. J. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally-mediated syncope induced by headup tilt. J.Am. Coll. Cardiol. 1993; 22: 1843-1848.
  22. Girolamo E. D., Iorio С D., Sabatini P. et al. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 1999; 33: 1227-1230.
  23. Zeng C, Zhu Z., Liu G. et al. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am. Heart J. 1998; 136: 852-858.
  24. Nelson S. D., Stanley M., Love C. J. et al. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch. Intern. Med. 1991; 151: 2425-2429.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2004

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##